. 2014 Aug 21;78(3):509–523. doi: 10.1111/bcp.12361

Table 1.

Demographic, clinical and pharmacogenetic characteristics of participants

	Model development				External evaluation
	Number	Mean	Median	95% observation interval	Number	Mean	Median	95% observation interval
Patients (Oslo / Brisbane)	69 / 173				72 / 0
Sex (Male / Female)	165 / 77				50 / 22
CYP3A5 genotype (^1/^1, ^1/^3, ^3/^3)^*	3 / 33 / 205				0 / 14 / 58
Age (years)		48	48	23–71		53	56	26–74
Height (cm)		173	175	152–193		175	175	159–192
Total body weight (kg)		82	80	51–121		77	77	50–99
Predicted fat free mass (kg)		57	59	35–80		56	59	35–71
Haematocrit (%)^†		33	33	25–43		33	33	27–43
Serum albumin (g l⁻¹)^†		36	36	24–45		–	–	–
Total serum bilirubin (μmol l⁻¹)^†		11	10	4–21		–	–	–
Aspartate aminotransferase (IU l⁻¹)^†		23	20	9–53		–	–	–
Alanine aminostransferase (IU l⁻¹)^†		33	26	11–91		–	–	–
Alkaline phosphatase (IU l⁻¹)^†		72	64	35–149		–	–	–
Prednisolone dose (mg day⁻¹)		21	20	5–36		20	20	15–31
Sampling time (days post-transplant)^†		267	20	5–2591		11	11	9–13
Total tacrolimus samples (Oslo / Brisbane)	3100 (1546 / 1554)				837 (837 / 0)
Tacrolimus samples per patient (Oslo / Brisbane)		13 (22 / 8)	8 (24 / 8)	4–40 (8–40 / 4–16)		12	12	9–15
Tacrolimus dose (mg twice daily)^† (Oslo / Brisbane)		5.8 (3.0 / 6.9)	6.0 (3.0 / 7.0)	1.0–10.0 (1.0–6.0 / 1.5–10.0)		3.0	3.0	1.8–5.0
Tacrolimus concentration (μg l⁻¹)^‡ (Oslo / Brisbane)		11.0 (7.0 / 15.0)	8.4 (6.1 / 13.1)	2.9–31.0 (2.5–16.6 / 4.2–35.9)		5.3	4.9	2.2–10.2

Brisbane, Brisbane dataset; CYP3A5, cytochrome P450 3A5; Oslo, Oslo dataset.

Frequency of CYP3A5 genotype was in Hardy–Weinberg equilibrium (Table S1). CYP3A5 genotype was established for all patients except one who was assigned to the most frequent genotype.

^†

Calculated from average within each patient.

^‡

Concentrations converted to liquid chromatography-tandem mass spectrometry equivalents if measured with immunoassay, see main text.